Sorafenib Unknown Status Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00722969Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer